Cell membrane camouflaged cerium oxide nanocubes for targeting enhanced tumor-selective therapy

J Mater Chem B. 2021 Dec 1;9(46):9524-9532. doi: 10.1039/d1tb01685g.

Abstract

Anticancer therapies with profound efficacy but negligible toxicity are a fundamental pursuit that has been made humanly possible through either targeting or tumor-selective therapeutic (TST) approaches. Herein, we developed a targeting-enhanced tumor-selective cancer therapy aimed at integrating the two approaches by preparing cerium oxide (CeO2) nanocubes with glucose oxidase (GOx) modified on the cube surface and cancer cell membrane (CCM) camouflaged outside. The immune escape and homotypic binding of camouflaged CCM enable targeted delivery of the resultant CeO2-GOx@CCM nanoparticles mostly into cancer tissue, while its acidic environment (pH < 6.6) activated a cascade reaction, in which the glucose was first catalyzed by GOx into H2O2 and then by CeO2 into highly cytotoxic ˙OH killing cancer cells. In the case of off-targeting, when very few CeO2-GOx@CCM nanoparticles were accidentally delivered into normal tissue, its neutral pH environment (pH = 7.4) triggered a protective reaction, in which the H2O2 generated was catalyzed by CeO2 into non-toxic H2O and O2. Both in vitro and in vivo results demonstrated that this targeting-enhanced TST achieved the most remarkable antitumor performance with negligible toxic side effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use*
  • Cell Membrane
  • Cerium
  • Drug Delivery Systems
  • Glucose Oxidase / chemistry
  • Glucose Oxidase / metabolism*
  • HeLa Cells
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Mice
  • Mice, Nude
  • Nanoparticles
  • Neoplasms
  • Neoplasms, Experimental
  • Purines
  • Random Allocation

Substances

  • Antineoplastic Agents
  • PH006 compound
  • Purines
  • Cerium
  • ceric oxide
  • Glucose Oxidase